Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01009593 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
A Phase 3 study, sponsored by Abbott.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,035
- Enrollment target
NCT01009593: Clinical Trial Phase 3 study, sponsored by Abbott.
NCT01009593 is a Phase 3 study that was terminated before completion, run by Abbott. The registered enrollment target is 1,035 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (34% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01009593, a Phase 3 study, was terminated before completion, sponsored by Abbott.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,035 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the overall survival (OS) of oral linifanib given as monotherapy once daily (QD) compared to sorafenib given twice daily (BID) per standard of care in subjects with advanced or metastatic HCC.
Interventions
- DRUG Sorafenib
- DRUG ABT-869
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,035 participants |
| Start Date | 2010-01 |
| Est. Completion | 2012-07 |
| Phase | Phase 3 |
Why NCT01009593 stopped before completion
NCT01009593 is an interventional study that assigns participants to a tested intervention. Its 1,035 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (34% higher).
The record links to 0 conditions, and to 2 interventions - of which Sorafenib is the first listed.
NCT01009593 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01009593 about?
NCT01009593 is a clinical study titled "Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)". The primary objective of this study is to assess the overall survival (OS) of oral linifanib given as monotherapy once daily (QD) compared to sorafenib given twice daily (BID) per standard of care in subjects with advanced or metastatic HCC.
What is the current status of trial NCT01009593?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,035 participants. The study started on 2010-01. Estimated completion is 2012-07.
What interventions are being tested in trial NCT01009593?
The interventions under investigation include: Sorafenib (DRUG), ABT-869 (DRUG).
Who is sponsoring clinical trial NCT01009593?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01009593's enrollment target sits among peer trials
1,035 287th of 2000 higher than 1,713 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05037682 · 1,035 participants · NA
Pain and Opioid Management in Older Adults
- NCT07282600 · 1,035 participants · Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
- NCT07345767 · 1,038 participants · NA
Hypknowledge Nationwide Sleep Extension
- NCT07084363 · 1,032 participants · NA
Quantitative Versus qUAlitative NeuromoniToring of neUroMuscular Block for Non-cardiothoracic Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia